Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Rhythm · Phase 3 · Completed · Enrollment 19

NCT05194124

ArmPopulationDoseWeeksEstimandWeight change
Run-in Period: Setmelanotide 2 mg QDBardet-Biedl Syndrome; POMC Deficiency2 mg1n/rn/r
Run-in Period: Setmelanotide 2.5 mg QDBardet-Biedl Syndrome; POMC Deficiency2.5 mg1n/rn/r
Run-in Period: Setmelanotide 3 mg QDBardet-Biedl Syndrome; POMC Deficiency3 mg1n/rn/r
DB Period: Setmelanotide 20 mg QWBardet-Biedl Syndrome; POMC Deficiency20 mg1n/rn/r
DB Period: Setmelanotide 25 mg QWBardet-Biedl Syndrome; POMC Deficiency25 mg1n/rn/r
DB Period: Setmelanotide 3 mg QDBardet-Biedl Syndrome; POMC Deficiency3 mg1n/rn/r
DB Period: Setmelanotide 30 mg QWBardet-Biedl Syndrome; POMC Deficiency30 mg1n/rn/r
OL Period: Setmelanotide 20 mg QWBardet-Biedl Syndrome; POMC Deficiency20 mg1n/rn/r
OL Period: Setmelanotide 25 mg QWBardet-Biedl Syndrome; POMC Deficiency25 mg1n/rn/r
OL Period: Setmelanotide 30 mg QWBardet-Biedl Syndrome; POMC Deficiency30 mg1n/rn/r